Related Experiment Videos

Improved lung compliance following indomethacin therapy in premature infants with persistent ductus arteriosus

Chest
|December 1, 1981
PubMed

Insights

Early indomethacin treatment for premature infants with patent ductus arteriosus (PDA) significantly improved lung compliance (CL) and tidal volume (VT). This suggests a potentially better clinical outcome for these infants.

Area of Science:

  • Neonatal Medicine
  • Pediatric Cardiology
  • Respiratory Physiology

Background:

  • Patent ductus arteriosus (PDA) is a common condition in premature infants.
  • PDA can lead to respiratory complications, including reduced lung compliance.
  • Indomethacin is a medication used to close PDA.

Purpose of the Study:

  • To evaluate the effect of intravenous indomethacin on dynamic lung compliance (CL) in premature infants with PDA.
  • To assess changes in echocardiographic parameters and respiratory mechanics following indomethacin therapy.

Main Methods:

  • A double-blind, controlled study involving 11 premature infants (6 control, 5 indomethacin).
  • Dynamic lung compliance (CL) and tidal volume (VT) were measured.
  • Echocardiography was used to assess left atrial/aortic root ratio (LA/Ao) and left ventricular end-diastolic dimension (LVEDD).

Main Results:

  • Indomethacin group showed a significant decrease in LA/Ao and LVEDD.
  • Indomethacin treatment led to a significant increase in tidal volume (VT) and lung compliance (CL).
  • Control group exhibited no significant changes in these parameters.

Conclusions:

  • Early indomethacin closure of PDA in premature infants improves dynamic lung compliance.
  • Improved lung compliance may positively impact the clinical course and outcomes of premature infants with PDA.
  • Indomethacin therapy offers a potential therapeutic benefit for respiratory function in this population.

Related Concept Videos